id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-304472-mi5v6512	Wilder-Smith, Annelies	Dengue vaccine development by the year 2020: challenges and prospects	2020-10-18		.txt	text/plain	4714	226	45	A plausible hypothesis is that CYD-TDV may trigger an immune response to dengue in seronegative persons that predisposes them to a higher risk of severe disease, analogue to what is seen in natural secondary dengue infections [16] . Two chimeric live-attenuated dengue vaccines are now in Phase 3 trials: one developed by Takeda (TAK-003) and one by the National Institute of Allergy and Infectious Diseases (TV003/TV005) (Table 1) . To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Robust and balanced immune responses to all 4 Dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-naive adults	./cache/cord-304472-mi5v6512.txt	./txt/cord-304472-mi5v6512.txt